TFS HealthScience and Appletree CI Group have joined together to expand expertise in ophthalmology and medical devices for improved patient impact.
Appletree CI Group
A niche CRO by CHOICE
Scope
Appletree CI Group is a specialized CSO (Contract Service Organization) in Winterthur, Switzerland offering services in clinical research and regulatory affairs.
At Appletree CI Group we believe in focusing on what we know best. Our core business is the development of ophthalmological and dermatological medicines, as well as medical device investigations. In addition, we are experts in pediatric studies and we offer regulatory affairs services (DRA, RA) worldwide.
Appletree is the only contract research organization (CRO) in Europe with the combined expertise of medical devices and ophthalmology.
Vision
Our vision:
Our ambition is to be known as the European address for clinical trials in ophthalmology, as well as for medical device investigations. Our international regulatory affairs expertise shall be renowned.
Values
Our values:
- Responsiveness
- Flexibility
- Mutual Respect
- Creativity/Inspiration
- Industry excellence
- Timeliness
Mission
Our mission:
- We ensure our clients’ success
- We combine our expertise with creative solutions
- We are always courteous, reliable and responsive
News
TFS Health Science Acquires Appletree CI Group, Expanding Expertise in Ophthalmology and Medical Devices for Improved Patient Impac
Click here to learn more about it.
ACG+ complies with the European General Data Protection Regulation 2016/679 (GDPR) as well as with the Swiss Federal Act on Data Protection.
Data Protection Responsible: Rolf Marugg (email: dataprotection[at]appletree-cig.com).
ARVO 2019 Annual Meeting – April 28 – May 2
We will be present at the Annual Meeting of the Association for Research in Vision and Ophthalmology (ARVO) from April 28 - May 02, 2019 in Vancouver, BC / USA. Dr. Mathis would be pleased to meet you in Vancouver. Please contact us for a meeting date.
ImaValve Public Summary
After 4 years the ImaValve project has been completed end of 2017. It resulted in the creation of a novel synthetic heart valve prosthesis, which has the potential to gradually transform inside the body into a living, durable aortic heart valve. The synthetic heart valve is delivered through a minimally invasive procedure, eliminating the need for open heart surgery. The prosthesis is expected to improve quality of life and reduce the burden of heart valve disease with significant social and economic benefits. Click here to read more about it.